Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.65 USD
Change Today -0.01 / -0.27%
Volume 332.9K
As of 5:20 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

cytrx corp (CYTR) Key Developments

CytRx Corporation Unveils Linker Activated Drug Release Technology Platform

CytRx Corporation has unveiled its proprietary Linker Activated Drug Release, or LADR, technology platform. LADR is a discovery engine designed to leverage the company's expertise in albumin biology and linker technology for the development of a new class of anticancer therapies. Among the cancers being pursued are liver, pancreatic, and non-small cell lung cancer. "LADR is a creative, novel approach to the development of next-generation therapeutic drug conjugates, which have rationally designed to control release in tumors of high-potency chemotherapeutics that are attached to either albumin or anticancer antibodies With the first drug candidates from this platform expected to enter the clinic in 2016.

CytRx Corporation Announces Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma

CytRx Corporation announced the interim results from its ongoing open-label Phase 2 pilot study evaluating the efficacy and safety of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients. For the study, patients with biopsy-confirmed KS were administered 100 or 150 mg/m2 aldoxorubicin (75 or 112 mg/m2 doxorubicin equivalents) IV every three weeks. At the time of presentation, preliminary analyses were available for nine patients who received at least six cycles of drug (mean = 6.3 cycles). Four patients had received prior Doxil chemotherapy. Of these 9 patients, 6 (67%) demonstrated a partial response (PR) to aldoxorubicin at the end of study visit (EOS), and 7 (78%) demonstrated PR within 4 months of EOS. Doxorubicin could be detected in all tumor biopsies and higher doxorubicin concentrations were demonstrated within KS lesions relative to skin next to the lesions for 3/4 (75%) patients for whom adequate tissue was available for analysis.Five of 6 (83%) patients receiving aldoxorubicin and for whom data are available exhibited reduced intratumoral viral loads during therapy. A subset of patients also exhibited improvements in quality of life during treatment, and all patients exhibited either improvement or stability in immunologic and virologic HIV treatment parameters. Aldoxorubicin was well-tolerated, with only 2 patients (22%) experiencing a grade 4 adverse event (transient neutropenia and anemia), and overall AEs (44%) were mild and compared favorably with AE rates from other trials enrolling KS patients representing urban, minority-predominant populations. This open-label Phase 2 clinical trial is expected to enroll up to 30 patients, randomly assigned to two equally sized treatment arms which will receive aldoxorubicin at 100 or 150 mg/m2 by 30-minute intravenous infusion. Because the KS patients in the study have compromised immune systems, the aldoxorubicin dosages administered in the trial are lower than those administered in the Company's clinical testing of aldoxorubicin in patients with soft tissue sarcomas. Patients with advanced KS receive aldoxorubicin on day 1, then every 3 weeks until evidence of tumor progression, unacceptable toxicity or withdrawal of consent. The primary objectives of preliminary efficacy include evaluation of the size, number and nodularity of skin lesions, change in size and number of lung lesions and changes in the number of tumor cells that express viral DNA (Kaposi sarcoma-associated herpesvirus, the etiologic agent of KS). The company is also evaluating the level of aldoxorubicin uptake into lesions. Safety is being assessed through monitoring of adverse events and the ability to remain on assigned treatment. The trial is being conducted at the Louisiana State University Health Sciences Center in New Orleans, LA.

CytRx Corporation Appoints Cheryl Cohen to its Board of Directors

CytRx Corporation announced the appointment of Cheryl Cohen, former Chief Commercial Officer of Medivation Inc., to its Board of Directors. Ms. Cohen served as the Chief Commercial Officer of Medivation Inc., from September 2011 to July 2014, where she was responsible for the company's U.S. launch of Xtandi (enzalutamide) for metastatic castration-resistant prostate cancer. Ms. Cohen currently serves as president of CLC Consulting. Ms. Cohen currently serves on the Board of Directors of Tokai Pharmaceuticals Inc. and Protein Sciences Corporation.

CytRx Corporation Announces Settlement of Stockholder Derivative Lawsuit in Delaware Court of Chancery

CytRx Corporation announced that it has reached an agreement to settle the stockholder derivative action pending in the Delaware Court of Chancery, which names as defendants a number of the company's current and former directors and officers, and names the company as a nominal defendant. The lawsuit, captioned In re CytRx Corp. Stockholder Derivative Litigation, C.A. No. 9864-VCL, relates to the company's issuance and pricing of stock options to its directors and officers in December 2013. Although the individual defendants have denied any liability or wrongdoing in connection with the allegations contained in the lawsuit, they believe that it is in the best interests of the company and its stockholders to settle the matter on reasonable terms to avoid potentially protracted and expensive litigation. The settlement provides that the company will re-price 2,095,000 stock options that were collectively granted on December 10, 2013 to Louis Ignarro, Joseph Rubinfeld, Marvin L. Selter, Richard L. Wennekamp, Steven A. Kriegsman, John Y. Caloz and Benjamin S. Levin, from the original exercise price of $2.39 to an exercise price of $4.66 (the share price at market closing on December 20, 2013). The settlement also provides that the company will implement certain corporate governance changes and modify certain governance practices regarding the granting of stock option grants. Under the settlement, it is not expected that the company will incur any out-of-pocket expenses. The parties have not yet reached an agreement on an amount of any award of fees and expenses to plaintiffs' attorneys. The settlement is subject to approval by the Delaware Court of Chancery and certain other conditions, including notice to the company's stockholders.

CytRx Corporation Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 01:30 PM

CytRx Corporation Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 01:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: David J. Haen, Vice President of Business Development and Investor Relations, Steven A. Kriegsman, Chairman, Chief Executive Officer and President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTR:US $3.65 USD -0.01

CYTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTR.
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2,039.5x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,387.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTRX CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at